Sangamo Therapeutics Inc (NASDAQ:SGMO) CFO Kathy Yi sold 5,000 shares of the stock in a transaction dated Monday, April 16th. The stock was sold at an average price of $19.83, for a total transaction of $99,150.00. Following the sale, the chief financial officer now directly owns 12,250 shares in the company, valued at $242,917.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Kathy Yi also recently made the following trade(s):
- On Thursday, March 15th, Kathy Yi sold 5,000 shares of Sangamo Therapeutics stock. The stock was sold at an average price of $25.56, for a total transaction of $127,800.00.
Sangamo Therapeutics stock traded down $0.05 during midday trading on Wednesday, reaching $19.47. The company had a trading volume of 2,450,300 shares, compared to its average volume of 2,205,452. The firm has a market capitalization of $1,545.47, a PE ratio of -27.89 and a beta of 2.80. Sangamo Therapeutics Inc has a 12-month low of $4.05 and a 12-month high of $27.50. The company has a current ratio of 5.54, a quick ratio of 5.54 and a debt-to-equity ratio of 0.13.
Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.03. The firm had revenue of $13.08 million for the quarter, compared to analyst estimates of $11.10 million. Sangamo Therapeutics had a negative net margin of 149.23% and a negative return on equity of 31.44%. Sangamo Therapeutics’s quarterly revenue was up 46.6% compared to the same quarter last year. During the same period last year, the company posted ($0.14) EPS. sell-side analysts predict that Sangamo Therapeutics Inc will post -0.15 EPS for the current fiscal year.
Several equities research analysts have recently issued reports on SGMO shares. Zacks Investment Research lowered shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, January 5th. BidaskClub lowered shares of Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday, March 17th. Barclays reissued a “buy” rating and set a $30.00 target price on shares of Sangamo Therapeutics in a research note on Sunday, February 25th. Wedbush reissued a “neutral” rating and set a $6.00 target price on shares of Sangamo Therapeutics in a research note on Monday, February 12th. Finally, Jefferies Group reissued a “buy” rating on shares of Sangamo Therapeutics in a research note on Friday, February 23rd. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Sangamo Therapeutics presently has an average rating of “Buy” and an average price target of $20.83.
A number of institutional investors have recently modified their holdings of SGMO. Fred Alger Management Inc. purchased a new position in Sangamo Therapeutics in the 4th quarter valued at about $148,000. Xact Kapitalforvaltning AB purchased a new position in Sangamo Therapeutics in the 4th quarter valued at about $175,000. Great West Life Assurance Co. Can lifted its stake in Sangamo Therapeutics by 150.3% in the 3rd quarter. Great West Life Assurance Co. Can now owns 12,767 shares of the biopharmaceutical company’s stock valued at $182,000 after buying an additional 7,667 shares in the last quarter. Chicago Equity Partners LLC purchased a new position in Sangamo Therapeutics in the 4th quarter valued at about $192,000. Finally, Jefferies Group LLC purchased a new position in Sangamo Therapeutics in the 4th quarter valued at about $295,000. 64.69% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: “Insider Selling: Sangamo Therapeutics Inc (SGMO) CFO Sells 5,000 Shares of Stock” was first published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.thelincolnianonline.com/2018/04/18/insider-selling-sangamo-therapeutics-inc-sgmo-cfo-sells-5000-shares-of-stock.html.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.